Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of STN1012600 versus latanoprost in primary open-angle glaucoma or ocular hypertension
jRCT2031220267Phase 3Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in open-angle glaucoma (OAG) and ocular hypertension comparing STN1012600 0.002% Arm with Latanoprost 0.005% Arm (2 arms). Primary endpoint: Change from baseline in mean diurnal intraocular pressure at Week 4. Started Aug 2022; status: completed.
02
Drugs
sepetaprostlatanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2031220267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220267.